News
  • Discover
  • Journals
  • Momentum
  • Rankings
  • Local
  • Trending
  • Latest
  • Top Stories
  • Rising
  • Controversial
  • Bubble Gap
  • Log in

Get above the noise

Log in for answers tailored to you — saved chats, your topics, and the full IJR suite.

Log in

IJR News

© IJR AI, Inc.

Privacy PolicyTerms of UseCookie PolicyInvestorsGet the appContact
Live
•Carly Simon Reveals Parkinson's Disease and Facial Cancer•Shanahan Limited Ahead of Melbourne Opener•France Wildfires Threaten Bordeaux, Spread to Spain•Bosa Reacts to Ryan Clark’s ESPN Firing•Romo Is Arrested in Milwaukee for OWI•US-Iran Pause to Resume Talks Amid Tensions•LeBron Signs with 76ers; Player Option Highlight•Black Sea Strife Escalates; India Calls Out Strikes•Paramount-Warner Deal Delayed to 2027 Amid Antitrust Challenges•European Wildfires Trigger Major Evacuations, Emergencies
•Carly Simon Reveals Parkinson's Disease and Facial Cancer•Shanahan Limited Ahead of Melbourne Opener•France Wildfires Threaten Bordeaux, Spread to Spain•Bosa Reacts to Ryan Clark’s ESPN Firing•Romo Is Arrested in Milwaukee for OWI•US-Iran Pause to Resume Talks Amid Tensions•LeBron Signs with 76ers; Player Option Highlight•Black Sea Strife Escalates; India Calls Out Strikes•Paramount-Warner Deal Delayed to 2027 Amid Antitrust Challenges
what's gaining coverage right now
🕹️ Today in the ArcadeWobble Rumble · ⚡ Golden AgePlay →✍️ Voices risingDCNF’s Thomas Phippen Interviews Sen. Marsha Blackburn · Daily Caller News Foundation · most read this weekRead →
Hormel Foods stock rises on steady earningsMarkets

Hormel Foods stock rises on steady earnings

Hormel Foods remains a defensive holding with about $12 billion in FY2023 revenue across its Retail, Foodservice and International segments, underpinned by steady earnings and dividend returns. Thermo Fisher Scientific is stabilizing in 2026, posting about $11.1 billion in Q1 revenue and guiding roughly $44 billion for the year as margins improve, with market views and valuation broadly balanced around fair value given its growth trajectory.

Jul 25, 2026
ImmuPharma Selects Thermo Fisher CDMO for KapiglucagonMarkets

ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon

ImmuPharma has named Thermo Fisher Scientific’s Patheon as the drug product CDMO for Kapiglucagon, following the earlier selection of Bachem for API manufacturing, as it pushes the glucagon prodrug toward IND-enabling development for Type 1 diabetes and potential dual-hormone artificial pancreas applications. The company is pursuing a streamlined regulatory path, potentially a 505(b)(2) in the U.S., with plans to file an IND and begin first-in-human studies subject to regulatory confirmation.

📍United States🏢FDA
Jul 22, 2026
•European Wildfires Trigger Major Evacuations, Emergencies